Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome.
- Published In:
- JCEM case reports, 2(10), luae177 (2024)
- Authors:
- Boesenkoetter, Jannes, Ellrichmann, Ina, Konukiewitz, Björn, Ellrichmann, Mark, Schulte, Dominik M
- Database ID:
- RPEP-07874
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07874APA
Boesenkoetter, Jannes; Ellrichmann, Ina; Konukiewitz, Björn; Ellrichmann, Mark; Schulte, Dominik M. (2024). Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome.. JCEM case reports, 2(10), luae177. https://doi.org/10.1210/jcemcr/luae177
MLA
Boesenkoetter, Jannes, et al. "Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome.." JCEM case reports, 2024. https://doi.org/10.1210/jcemcr/luae177
RethinkPeptides
RethinkPeptides Research Database. "Efficacy of Racecadotril in a Patient Affected by a Therapy-..." RPEP-07874. Retrieved from https://rethinkpeptides.com/research/boesenkoetter-2024-efficacy-of-racecadotril-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.